Sugi Predict

Sugi Predict / Targets / IPO7

IPO7

Importin-7 · O95373 · IPO7 on Sugi Atlas →

0 patent compounds predicted against IPO7, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to IPO7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection PHASE3COMPLETED
Ivermectin and Nitazoxanide Combination Therapy for COVID-19 PHASE2/PHASE3UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Efficacy of Ivermectin in COVID-19 PHASE1/PHASE2COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma PHASE2RECRUITING
Reverse Transcriptase Inhibitors in AGS PHASE2COMPLETED
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma PHASE1COMPLETED
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Pulmonary Hypertension--Mechanisms and Family Registry nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic nanCOMPLETED
Treatment of Chronic Lymphocytic Leukemia nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
MEHMO Natural History and Biomarkers nanRECRUITING
Genetic Studies Spermatogenic Failure nanCOMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias nanCOMPLETED
Cause of Familial Testicular Cancer nanCOMPLETED
Microarray Analysis in Syndromic Obesity nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a IPO7 binder may also engage these)

ProteinNameSimilarity
Q9EPL8 — 1.000 Q9EPL8 →
IPO8 Importin-8 0.996 landscape →
Q7TMY7 — 0.996 Q7TMY7 →
Q9CRT8 — 0.994 Q9CRT8 →
F4J738 — 0.993 F4J738 →
Q5SPJ8 — 0.989 Q5SPJ8 →
IPO11 Importin-11 0.988 landscape →
F4IRR2 — 0.987 F4IRR2 →
Q8BKC5 — 0.986 Q8BKC5 →
IPO5 Importin-5 0.986 landscape →
A5WW24 — 0.985 A5WW24 →
Q8K2V6 — 0.985 Q8K2V6 →
Q5RA02 — 0.982 Q5RA02 →
XPOT Exportin-T 0.981 landscape →
PDS5A Sister chromatid cohesion protein PDS5 homolog A 0.980 landscape →
Q91YE6 — 0.979 Q91YE6 →
Q6A026 — 0.979 Q6A026 →
Q5F3U9 — 0.979 Q5F3U9 →
A1L1F4 — 0.979 A1L1F4 →
A0A0R4ITC5 — 0.978 A0A0R4ITC5 →
XPO5 Exportin-5 0.978 landscape →
TRRAP Transformation/transcription domain-associated protein 0.978 landscape →
ATP6V1H V-type proton ATPase subunit H 0.978 landscape →
Q6TRW4 — 0.978 Q6TRW4 →
Q5F3V3 — 0.978 Q5F3V3 →
IPO9 Importin-9 0.978 landscape →
Q4VA53 — 0.978 Q4VA53 →
Q498H0 — 0.977 Q498H0 →
F1R2X6 — 0.977 F1R2X6 →
Q6GQ80 — 0.977 Q6GQ80 →